Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...
Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...
Since its launch, Isomorphic Labs has focused on using AI to model biological processes and accelerate drug discovery. The company co-developed AlphaFold 3 with Google DeepMind, an AI model ...
Isomorphic Labs is raising money in its first-ever external funding round from Thrive Capital, a big backer of ChatGPT developer OpenAI ...